ReviewExpert opinion on pharmacotherapy2015
An update on pharmacotherapy for leishmaniasis.
Review in Expert opinion on pharmacotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed, 3 syntheses or guidelines pooled it, 304 citations in OpenAlex.
- Plant-based therapeutics for leishmaniasis: A systematic review emphasizing human studies and clinical trial evidence.PLoS neglected tropical diseases · 2026Pooled it
- Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2021Pooled it
- Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform.PLoS neglected tropical diseases · 2017Pooled it
- A phase Ib/II clinical study to evaluate the safety and efficacy of topical Arnica tincture to treat non-complicated cutaneous leishmaniasis in Colombia.PLoS neglected tropical diseases · 2025Trial
- Differences in the Cellular Immune Response during and after Treatment of Sudanese Patients with Post-kala-azar Dermal Leishmaniasis, and Possible Implications for Outcome.Journal of epidemiology and global health · 2024Trial
- Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India.PLoS neglected tropical diseases · 2018Trial
- Thermoresponsive Nanogel IncorporatingACS omega · 2026Article
- Optimisation of a Topical Miltefosine Carbopol-Based Gel for Cutaneous Leishmaniasis: Antileishmanial Activity After Storage and Drug Response.Gels (Basel, Switzerland) · 2026Article
- A Chronic Ulcer in a Patient Under Biologic Treatment: A Quiz.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- rK39-Negative Visceral Leishmaniasis with Renal Complications from Eastern Uttar Pradesh, India: A Case-Based Clinico-Entomological Investigation Suggesting Possible Local Transmission.Acta parasitologica · 2026Article
- Pediatric Measles and Visceral Leishmaniasis Co-infection: Diagnostic Challenges and Insights Into Pathophysiology.Cureus · 2026Article
- Bone Marrow-Derived Mesenchymal Stem Cells Alleviate Cutaneous Leishmaniasis by Promoting M2 Macrophage Polarization and Skin Tissue Repair in a Murine Model.Biomolecules · 2026Article
- Pleural Effusion Revealing Visceral Leishmaniasis: A Diagnostic Pitfall in an Immunocompetent Patient.Cureus · 2026Article
- Validation of a Graphite Furnace Atomic Absorption Spectrometry (GFAAS) Method for Determining Total Antimony in Organs of Mice.ACS omega · 2026Article
- Protective Effects of rLPG3 Plus Freund's Incomplete Adjuvant on Parasitism, Hepatic Function, and Immune Modulation in Experimental Visceral Leishmaniasis.ACS infectious diseases · 2026Article
- Natural product-based therapeutic strategies againstFrontiers in microbiology · 2026Review
- Mannose-engineered nanoparticles for site-specific delivery of fluconazole to treat cutaneous leishmaniasis.PeerJ · 2026Article
- Revisiting visceral leishmaniasis in immunocompromised patients: Ongoing gaps and advances in diagnostics, therapies, and preventive measures.Current research in parasitology & vector-borne diseases · 2026Review
- Post-kala-azar dermal leishmaniasis: insights into underlying pathogenic mechanisms and genetic landscape.Frontiers in microbiology · 2026Review
- Nanoformulation-Based Transdermal Drug Delivery: A Paradigm Shift in Antiparasitic Therapy for Zoonotic Diseases.Pharmaceutics · 2025Review
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionLeishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is challenging and the armamentarium of drugs is small, duration of treatment is long, and most drugs are toxic. AREAS COVERED: A literature search on treatment of leishmaniasis was done on PubMed. Single dose of liposomal amphotericin B (L-AmB) and multidrug therapy (L-AmB + miltefosine, L-AmB + paromomycin (PM), or miltefosine + PM) are the treatment of choice for VL in the Indian subcontinent. A 17-day combination therapy of pentavalent antimonials (Sb(v)) and PM remains the treatment of choice for East African VL. L-AmB at a total dose of 18 - 21 mg/kg is the recommended regimen for VL in the Mediterranean region and South America. Treatment of CL should be decided by the severity of clinical lesions, etiological species and its potential to develop into mucosal leishmaniasis. EXPERT OPINION: There is an urgent need to implement a single-dose L-AmB or combination therapy in the Indian subcontinent. Shorter and more acceptable regimens are needed for the treatment of post - kala-azar dermal leishmaniasis. Combination therapy with newer drugs needs to be tested in Africa. Due to the toxicity of systemic therapy, a trend toward local treatment for New World CL is preferred in patients without risk of mucosal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.